Jubilant Pharmova Limited (BOM:530019)
India · Delayed Price · Currency is INR 973.45
+3.70 (0.38%)
At close: Jun 5, 2026
Jubilant Pharmova Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Jubilant Pharmova stock has a consensus rating of "Strong Buy" and an average price target of ₹1,244. The average 1-year stock price forecast is 27.79% higher than the current stock price, while the lowest is ₹1,140 (+17.11%) and the highest is ₹1,348 (+38.48%).
Price Target: ₹1,244 (+27.79%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jubilant Pharmova stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Jan '26 | Feb '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
95.33B
from 82.80B
Increased by 15.14%
Revenue Next Year
108.29B
from 95.33B
Increased by 13.60%
EPS This Year
37.65
from 27.49
Increased by 36.95%
EPS Next Year
50.80
from 37.65
Increased by 34.93%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 |
|---|---|---|
| High | 96.9B | |
| Avg | 95.3B | |
| Low | 93.7B |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 17.1% | |
| Avg | 15.1% | |
| Low | 13.2% |
EPS Forecast
| EPS | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | 37.65 | |
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | 37.0% | |
| Low | - |